BG Medicine(美國)

BG Medicine

美國BGMedicine,Inc.www.bg-medicine.comBGMedicine是一家致力于發(fā)現(xiàn)、開發(fā)和商品化以生物標志物為基礎(chǔ)的新型分子診斷技術(shù)，并借此來改善患者治療結(jié)果和控制醫(yī)療費用的生命科學(xué)公司。該公司宣布，在D輪融資中獲得總額為4000萬美元的資金。此輪融資包括新投資者LeggMasonCapitalManagement、GEAssetManagement、SMALLCAPWo rldFund和現(xiàn)有投資者FlagshipVentures、GildeHealthcarePartners、Humana、SteliosPapadopoulos。該筆資金將用于推動公司現(xiàn)有的兩個診斷產(chǎn)品的研發(fā)和商業(yè)化，并將支持公司繼續(xù)進行其他產(chǎn)品的研發(fā)。BGMedicineisalifesciencescompanyfocusedonthediscovery,developmentandcommercializationofnovelmoleculardiagnosticsbasedonbiomarkerstoimprovepatientoutcomesandcontainhealthcarecosts.Ourtechnologyplatformuniquelypositionsustorapidlyandcost-effectivelydiscovernewhigh-valuebiomarkersoverabroadrangeoftherapeuticcategoriesthatpromisetobehighlycorrelatedtoclinicaloutcomes.Wehavebuiltabroadproductpipelinethatfocusesoncardiovasculardisease,cancerandCNSdisordersthroughacademiccollaborationsandinitiativeswithmajorpharmaceuticalcomp